Verve Therapeutics
Price & Volume
Stats
See moreOpen | $4.46 |
Previous Close | $4.59 |
Day Range | $4.39-$5.47 |
52W Range | $2.86-$9.30 |
Market Cap | $407.5M |
Shares Short | 16M |
Financials
See moreRevenue (12 Mos) | $32.3M |
Revenue Growth (YoY) | 154.3% |
Gross Profit (12 Mos) | $9.4M |
Diluted EPS | -$2.35 |
News
See moreYahoo Finance • 6 days ago
Why Verve Therapeutics Is Skyrocketing Today
Yahoo Finance • 8 days ago
Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
Yahoo Finance • 11 days ago
Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
Yahoo Finance • 17 days ago
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
About
CEO | Dr. Sekar Kathiresan M.D. |
CFO | Ms. Allison Dorval CPA |
Address | 201 Brookline Avenue, Boston, MA, United States, 02215 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 274 |
